Albany, NY -- (SBWire) -- 10/02/2018 --A recent report by ResearchMoz.us, titled, "Global Meningococcal Vaccine Market Research Report 2018," finds that the market would rise steadily in the next couple years. The report arrives at the conclusion after carefully examining the headwinds and tailwinds affecting the market and also the current and historical figures.

At the outset the report describes a meningococcal vaccine as one that can thwart infection by Neisseria meningitides. The vaccines are almost 85% to 100% effective for a minimum of two years in reducing occurrence of meningitis and sepsis in people. This has stoked demand in the global meningococcal vaccine market. The vaccine is administered by an injection into the muscle or under the skin.

The global meningococcal vaccine market is being propped up by the affordable prices of medicines and public private partnerships for conducting research and development. As a result, there are quite a few vaccines in the pipeline. With their commercial, the global meningococcal market would receive a further boost. Other factors proving beneficial for the global meningococcal vaccine market are different awareness programs by governments and efforts by authorities to better healthcare facilities. This has been prompted by the rising instances of deaths caused by meningococcal diseases. The MenA Conjugate Vaccine Programs in Africa, for instance, is predicted to stop 123,000 deaths from occurring by 2018.

Get a sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1821313

The different types of vaccines available in the global meningococcal vaccine market are haemophilus influenza type b vaccine, pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and meningococcal vaccine, among others. Among them, the segment of meningococcal vaccine is predicted to see good growth in sales in the next couple of years. It is further comprised of serogroup B meningococcal vaccines and meningococcal conjugate vaccines.

The global meningococcal vaccine market is bifurcated on the basis of end users into children and adults. Among them, demand from children is predicted to rise at the highest pace in the next couple of years. This is because bacterial meningitis affects children mainly. The main distribution channels in the global meningococcal vaccine market are retail pharmacies, hospital pharmacies, and others. Among those, the hospital pharmacies are likely see higher sales in the near term.

From a geographical standpoint, the global meningococcal vaccine market is being powered mainly by North America. The presence of quite a few prominent vaccine manufacturers and increased knowledge about the benefits of immunization have mainly promoted the market in the region. Asia Pacific is predicted to emerge as another key market because of the rising knowledge about such immunizations and high prevalence of bacterial meningitis in North Korea and Thailand.

Some of the key players in the global meningitis vaccine market are GlaxoSmithKline, plc, Pfizer, Inc., Merck & Co., Inc., Astellas Pharma Inc., Sanofi Pasteur SA, Emergent BioSolutions, Inc., CSL Limited, and Johnson & Johnson.